Tirzepatide tablets vs injections: clearing up the biggest confusion

The myth: there's a tirzepatide pill you can take instead of injecting

This is probably the most common question our prescribers field. People have heard about oral GLP-1 medicines and reasonably assumed that tirzepatide comes in a tablet form as well as a pen. That assumption is understandable — but it is not correct for the UK market right now.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, and it is only licensed in the UK as a subcutaneous injection. The Mounjaro KwikPen delivers the medicine once a week into the fat beneath the skin of your abdomen, thigh or upper arm. Each pre-filled pen contains four weekly doses. That is the only form you can be legitimately prescribed in the UK for weight management. More on how the injectable form works is available if you want the mechanism in more depth.

Where does the tablet idea come from? Partly from global news about oral GLP-1 medicines being in development or approved elsewhere, and partly because a different molecule (semaglutide) does now exist as a licensed oral weight-management tablet in the UK (approved by the MHRA on 11 June 2026 as Wegovy tablets). That is not tirzepatide. It is a separate drug, a separate mechanism, and a separate licensed product. Conflating the two is an easy mistake, but it matters clinically.

If you have seen social-media posts or forum threads describing a tirzepatide capsule or pill available in the UK, treat that with caution. A medicine that is not licensed here cannot be legally supplied to you by a UK pharmacy, and buying injectable or tablet GLP-1 medicines from unverified sellers carries real safety risks, the MHRA's Yellow Card scheme allows anyone to report suspect sellers.

What the injection schedule looks like in practice

If needles are the thing putting you off, it helps to know what the injection actually involves day-to-day. The Mounjaro KwikPen is pre-filled and pre-set, you press it against the skin, activate it, and the dose is delivered in a few seconds. You do not draw up a syringe. You do not adjust a dial. Most people who were apprehensive find the physical act of injecting far less daunting than they expected after the first one or two attempts. A step-by-step guide to injecting tirzepatide covers the technique clearly.

Storage-wise, the pen lives in the fridge at 2–8°C between uses, many people keep it in the fridge door next to everyday items, which makes the weekly ritual easy to remember. There is a limited window during which a pen can be kept at room temperature, but the exact length of that window is specified in the Patient Information Leaflet and on the Mounjaro SmPC on the eMC, always check there rather than relying on what a website tells you.

Treatment starts at 2.5mg, a dose sized for your body to adjust, not for maximum effect. The prescriber typically reviews and increases the dose in four-week steps. UK strengths run from 2.5mg up to 15mg. An overview of tirzepatide for weight loss covers the full dosing context if that is useful background.

Tirzepatide injection vs oral semaglutide: a factual comparison

Since oral semaglutide (Wegovy tablets) is the closest real-world parallel to a tirzepatide tablet, it is worth comparing the two honestly. They are not equivalent molecules, they work differently, and the trial populations differ, so direct head-to-head numbers do not exist. What follows is the evidence as it stands.

The trial figures are not directly comparable) different molecules, different durations, different participant groups. What they show is that both medicines can produce meaningful weight reduction, with tirzepatide's trial results currently sitting higher on average. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, compared tirzepatide with semaglutide 2.4mg injection and found greater average weight reduction with tirzepatide over 72 weeks. No equivalent head-to-head exists yet against oral semaglutide.

Which one is right for a given person depends on their health picture, preferences and circumstances. Some people find daily tablet-taking easier to fit into their routine. Others prefer the set-and-forget quality of a weekly injection. Neither preference is wrong. That is exactly the kind of conversation to have during a free consultation with our prescribers, where the clinical fit (not just the format) gets assessed properly.

Eligibility and the clinical assessment you will need either way

Both tirzepatide injection and oral semaglutide tablets are prescription-only medicines. That fact does not change with the format. A prescriber must assess your health before either can be supplied, and a UK pharmacy must be able to verify it can legally dispense to you.

For tirzepatide (Mounjaro), the licensed eligibility is adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. NICE recommends tirzepatide for NHS use in adults with a BMI of 35 or more plus at least one weight-related comorbidity, the private route through a regulated pharmacy like nume does not require meeting NHS criteria. You can check whether you might be eligible via the NHS BMI calculator as a starting point, but eligibility is always confirmed by the prescriber.

Our clinical team reviews every consultation personally. There is no automated decision. If you want to understand who leads that process, our clinical team page gives you the detail. Which medicine suits you is a clinical decision our prescribers make with you, and our guide to tirzepatide oral vs injection can help you think through the format question before that conversation.